Brussels, my love? Déjà vu - Europe's migration muddle
In this edition of our talk show Brussels, my love?, we discuss the EU's response to the migration crisis on the Italian island of Lampedusa and the EU's dream to have zero pollution by 2050.
The current EU Parliament and Commission had just begun the work of their five-year agenda when it was derailed by Covid-19 and then the Ukraine war. As the institutions' mandate enters a final phase, Real Economy gets the views of key players in Brussels on one of the EU's most difficult chapters.
Credit: euronews (in English) Duration: 08:00Published
Law enforcement on Tuesday morning conducted searches in the Brussels offices of Maximilian Krah, the far-right MEP whose assistant has been arrested for allegedly spying for China.
Credit: euronews (in English) Duration: 01:28Published
The next EU Commission will have to cope with a legacy of debt accummulated out of necessity by its predecessor in response to the Covid crisis and the Ukraine War. Instruments are in place to both control debt and invest in the future, but challenging times lie ahead.
Credit: euronews (in English) Duration: 00:56Published
The White House said it was "deeply troubled" that parliament had passed the bill. The UK, Germany, Italy and France have also all urged Georgia to withdraw it.
Credit: euronews (in English) Duration: 02:25Published
PM Narendra Modi confident of overwhelming BJP victory in Lok Sabha elections, plans to attend G7 summit in Italy after taking oath as PM, as announced on Aaj.. IndiaTimes
New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .
NBC reports that patients taking
Novo Nordisk's obesity treatment maintain
an average of 10% weight loss over four years.
The news potentially boosts the
drugmaker's push for Wegovy to be
covered by insurers and governments. .
The company submitted long-term
findings at the European Congress
on Obesity in Venice, Italy. .
This is the longest study
we’ve conducted so far of
semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.
We see that once the majority
of the weight loss is accrued,
you don’t go back and start
to increase in weight
if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.
According to another analysis published by
the drugmaker, approximately 17% of trial participants stopped using the treatment
due to side effects like nausea. .
The costly treatment ranges from $200
to nearly $2,000 per month in the ten
countries where the drug is available.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
Rival Eli Lilly launched its drug
Zepbound in the United States
in December of 2023. .
Neither drugmaker has managed
to produce enough of the
treatment to meet surging demand
Credit: Wibbitz Top Stories Duration: 01:31Published
Prior to her Monday meetings with Italian political leaders, von der Leyen was a guest on national TV, where she spoke about the need to defend Ukraine against Russia's aggression to preserve peace in Europe.
Credit: euronews (in English) Duration: 02:00Published